Advertisements



GlaxoSmithKline And Merck KGaA Position For The Next Wave In Immuno-Oncology

GlaxoSmithKline And Merck KGaA Position For The Next Wave In Immuno-Oncology.....»»

Category: topSource: seekingalphaFeb 11th, 2019

GSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy......»»

Category: topSource: reutersFeb 5th, 2019

GlaxoSmithKline and Merck KGaA strike immunotherapy deal worth up to $4 billion

U.K.-based GlaxoSmithKline Plc ¬†and Germany-based Merck KGaA are entering a partnership to develop and commercialize a therapy for patients with advanced non-small cell lung cancer in a deal worth up to $4.23 billion, the companies announced Tuesday......»»

Category: topSource: marketwatchFeb 5th, 2019

GlaxoSmithKline and Merck KGaA to strike immunotherapy deal worth up to $4.23 billion

U.K.-based GlaxoSmithKline plc a.....»»

Category: topSource: marketwatchFeb 5th, 2019

GlaxoSmithKline, Merck KGaA to collaborate on cancer treatments

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchFeb 5th, 2019

Merck KGaA to receive upfront payment of about $342.8 mln as part of GlaxoSmithKline collaboration

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchFeb 5th, 2019

Merck KGaA could receive up to about $4.2 bln in milestone payments as part of GlaxoSmithKline deal

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchFeb 5th, 2019

Merck, Bristol-Myers profits rise on cancer drug sales

Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments......»»

Category: topSource: reutersOct 25th, 2018

BioLineRx expands immuno-oncology collaboration with Merck

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 30th, 2018

Merck upgraded to Overweight on immuno-oncology leadership at Morgan Stanley

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 17th, 2018

Merck KGaA wins U.S. CRISPR patent

Germany-based Merck KGaA has won a U.S. patent for a CRISPR technology that helps make the gene-editing technique more efficient, the company announced Tuesday. Merck .....»»

Category: topSource: marketwatchFeb 19th, 2019

Merck KGaA is expanding its R&D hub in the U.S.

EMD Serono, an affiliate of Merck KGaA,.....»»

Category: realestateSource: bdcnetworkFeb 15th, 2019

This Stock Will Ride the Next Wave of Industrial Manufacturing

The computer-aided-design company PTC is nearing the end of a successful switch in business models and is in position to be a winner in the industrial Internet of Things......»»

Category: topSource: barronsFeb 11th, 2019

This Stock Will Ride the Next Wave in Industrial Manufacturing

The computer-aided design company PTC is nearing the end of a successful switch in business models and is in position to be a winner in the industrial Internet of Things......»»

Category: topSource: barronsFeb 7th, 2019

Glaxo Inks Deal With Merck KGaA to Co-Develop Cancer Candidate

Zacks.....»»

Category: topSource: redinewsFeb 6th, 2019

Glaxo Inks Deal With Merck KGaA to Co-Develop Cancer Candidate

Glaxo (GSK) signs a co-development and commercialization agreement with Germany-based Merck K.....»»

Category: personnelSource: nytFeb 6th, 2019

Stellar Biotechnologies Reports First Quarter Financial Results

LOS ANGELES, Feb. 5, 2019 /PRNewswire/ -- Stellar Biotechnologies, Inc. (NASDAQ:SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, today reported fi.....»»

Category: earningsSource: benzingaFeb 5th, 2019

GSK, Merck KGaA partner to jointly develop cancer treatment M7824

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 5th, 2019

Merck KGaA CEO sees high demand for semiconductor solutions, Bloomberg says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 1st, 2019

Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds

Merck KGaA (MKGAF) inks an exclusive licensing agreement with Vertex for two DNA-dependent protein kinase inhibitors in the field of gene editing for six specific g.....»»

Category: dealsSource: nytJan 25th, 2019

Merck KGaA grants license to Vertex for two DNA damage response inhibitors

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 24th, 2019